SCHEMBL6183637

SCHEMBL6183637

CC(C)CCN(C(=O)c1ccc(-c2csc(NC(=O)c3ccncc3)n2)cc1)C(=O)N(C)C#N

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.51
TSHR P16473 3/20 0.49
MAPK1 P28482 3/20 0.49
KDM4E B2RXH2 2/20 0.49
USP2 O75604 1/20 0.49
HPGD P15428 1/20 0.49
ROCK1 Q13464 4/20 0.45
ROCK2 O75116 3/20 0.45
MAPT P10636 3/20 0.45
ALDH1A1 P00352 1/20 0.45
THRB P10828 1/20 0.45
LMNA P02545 3/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
MPL P40238 2/20 0.43
PHGDH O43175 1/20 0.43
KMT2A Q03164 1/20 0.42
ATM Q13315 1/20 0.42
STAT3 P40763 1/20 0.42
HSD17B10 Q99714 1/20 0.42
SCD O00767 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6183641 0.87 TSHR (0.50) PARP1TSHRMAPK1KDM4EUSP2
SCHEMBL6183359 0.75 ENPP2 (0.46) TSHRMAPK1KDM4EUSP2MAPT
SCHEMBL7544949 0.74 RAB9A (0.49) TSHRMAPK1KDM4EMAPTALDH1A1
SCHEMBL12248876 0.72 PARP1 (0.76) PARP1TSHRMAPK1KDM4EROCK1
SCHEMBL6183646 0.72 PARP1 (0.52) PARP1TSHRMAPK1KDM4EUSP2
SCHEMBL7486512 0.72 CTSB (0.50) PARP1MAPK1MAPTSMN1; SMN2MPL
SCHEMBL7586301 0.72 MAPT (0.56) TSHRMAPK1USP2MAPTALDH1A1
SCHEMBL7490691 0.71 CTSB (0.51) PARP1MAPK1MAPTALDH1A1LMNA
SCHEMBL12249044 0.71 PARP1 (0.78) PARP1TSHRMAPK1ROCK1ROCK2
SCHEMBL1883429 0.71 PARP1 (0.74) PARP1KDM4EROCK1ROCK2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2001068645-A2 N-CYANOMETHYLCARBOXAMIDES AND THEIR USE AS PROTEASE INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2001-09-20 WO claimed
EP-1161415-B1 N-CYANOMETHYLAMIDES AS PROTEASE INHIBITORS AXYS PHARM INC (US) 2005-07-13 EP disclosed
US-6593327-B2 N-cyanomethyl amides which are cysteine protease inhibitors; treating osteoporosis; mixtures with bisphosphonates AXYS PHARMACEUTICALS, INC. 2003-07-15 US disclosed
US-20030119788-A1 Novel compounds and compositions as protease inhibitors AXYS PHARMACEUTICALS, INC. (US) 2003-06-26 US disclosed
US-6476026-B1 Compounds and compositions as protease inhibitors AXYS PHARMACEUTICALS, INC. 2002-11-05 US disclosed
US-20020086996-A1 Novel compounds and compositions as protease inhibitors AXYS PHARMACEUTICALS, INC. (US) 2002-07-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020086996-A1 Novel compounds and compositions as protease inhibitors CTRL, SERPINB1, CPN1 PARP1 1278/4885TSHR 4863/4885MAPK1 2648/4885
US-20030119788-A1 Novel compounds and compositions as protease inhibitors CTRL, SERPINB1, CPN1 PARP1 1278/4885TSHR 4863/4885MAPK1 2648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.